Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson
21 janv. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD...
Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
16 janv. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
11 déc. 2019 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
08 nov. 2019 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling...
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
06 nov. 2019 16h15 HE
|
Bellicum Pharmaceuticals, Inc.
Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to...
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
31 oct. 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
30 oct. 2019 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT - HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
CORRECTING and REPLACING - Bellicum Pharmaceuticals, Inc.
16 août 2019 10h52 HE
|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent...
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
16 août 2019 08h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm
31 mai 2019 19h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). ...